Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 148

1.

Plac1 Is a Key Regulator of the Inflammatory Response and Immune Tolerance In Mammary Tumorigenesis.

Yuan H, Wang X, Shi C, Jin L, Hu J, Zhang A, Li J, Vijayendra N, Doodala V, Weiss S, Tang Y, Weiner LM, Glazer RI.

Sci Rep. 2018 Apr 9;8(1):5717. doi: 10.1038/s41598-018-24022-w.

2.

Hyperactivation of nuclear receptor coactivators induces PERK-dependent cell death.

Hossain MM, Barua D, Arabkari V, Islam N, Gupta A, Gupta S.

Oncotarget. 2018 Feb 8;9(14):11707-11721. doi: 10.18632/oncotarget.24451. eCollection 2018 Feb 20.

3.

High RAC3 expression levels are required for induction and maintaining of cancer cell stemness.

Panelo LC, Machado MS, Rubio MF, Jaworski F, Alvarado CV, Paz LA, Urtreger AJ, Vazquez E, Costas MA.

Oncotarget. 2017 Dec 22;9(5):5848-5860. doi: 10.18632/oncotarget.23635. eCollection 2018 Jan 19.

4.

MAD2L2 inhibits colorectal cancer growth by promoting NCOA3 ubiquitination and degradation.

Li Y, Li L, Chen M, Yu X, Gu Z, Qiu H, Qin G, Long Q, Fu X, Liu T, Li W, Huang W, Shi D, Kang T, Luo M, Wu X, Deng W.

Mol Oncol. 2018 Mar;12(3):391-405. doi: 10.1002/1878-0261.12173. Epub 2018 Feb 13.

5.

Cancer Stem Cell Phenotypes in ER+ Breast Cancer Models Are Promoted by PELP1/AIB1 Complexes.

Truong TH, Hu H, Temiz NA, Hagen KM, Girard BJ, Brady NJ, Schwertfeger KL, Lange CA, Ostrander JH.

Mol Cancer Res. 2018 Apr;16(4):707-719. doi: 10.1158/1541-7786.MCR-17-0598. Epub 2018 Jan 18.

PMID:
29348189
6.

The regulatory roles of long non-coding RNAs in the development of chemoresistance in breast cancer.

Malhotra A, Jain M, Prakash H, Vasquez KM, Jain A.

Oncotarget. 2017 Nov 8;8(66):110671-110684. doi: 10.18632/oncotarget.22577. eCollection 2017 Dec 15. Review.

7.

HER2-Driven Breast Tumorigenesis Relies upon Interactions of the Estrogen Receptor with Coactivator MED1.

Yang Y, Leonard M, Zhang Y, Zhao D, Mahmoud C, Khan S, Wang J, Lower EE, Zhang X.

Cancer Res. 2018 Jan 15;78(2):422-435. doi: 10.1158/0008-5472.CAN-17-1533. Epub 2017 Nov 29.

PMID:
29187405
8.

Relation among Aromatase P450 and Tumoral Growth in Human Prolactinomas.

García-Barrado MJ, Blanco EJ, Iglesias-Osma MC, Carretero-Hernández M, Catalano-Iniesta L, Sanchez-Robledo V, Carretero M, Herrero JJ, Carrero S, Carretero J.

Int J Mol Sci. 2017 Nov 1;18(11). pii: E2299. doi: 10.3390/ijms18112299. Review.

9.

PPARs as determinants of the estrogen receptor lineage: use of synthetic lethality for the treatment of estrogen receptor-negative breast cancer.

Glazer RI, Kopelovich L.

Oncotarget. 2017 Apr 20;8(31):50337-50341. doi: 10.18632/oncotarget.17302. eCollection 2017 Aug 1.

10.

Prognostic and predictive importance of the estrogen receptor coactivator AIB1 in a randomized trial comparing adjuvant letrozole and tamoxifen therapy in postmenopausal breast cancer: the Danish cohort of BIG 1-98.

Alkner S, Jensen MB, Rasmussen BB, Bendahl PO, Fernö M, Rydén L, Mouridsen H; Danish Breast Cancer Cooperative Group.

Breast Cancer Res Treat. 2017 Nov;166(2):481-490. doi: 10.1007/s10549-017-4416-0. Epub 2017 Aug 1.

11.

Role of steroid receptor and coregulator mutations in hormone-dependent cancers.

Groner AC, Brown M.

J Clin Invest. 2017 Apr 3;127(4):1126-1135. doi: 10.1172/JCI88885. Epub 2017 Apr 3. Review.

12.

The Role of PI3K Isoforms in Regulating Bone Marrow Microenvironment Signaling Focusing on Acute Myeloid Leukemia and Multiple Myeloma.

Piddock RE, Bowles KM, Rushworth SA.

Cancers (Basel). 2017 Mar 28;9(4). pii: E29. doi: 10.3390/cancers9040029. Review.

13.

SPOP Mutation Drives Prostate Tumorigenesis In Vivo through Coordinate Regulation of PI3K/mTOR and AR Signaling.

Blattner M, Liu D, Robinson BD, Huang D, Poliakov A, Gao D, Nataraj S, Deonarine LD, Augello MA, Sailer V, Ponnala L, Ittmann M, Chinnaiyan AM, Sboner A, Chen Y, Rubin MA, Barbieri CE.

Cancer Cell. 2017 Mar 13;31(3):436-451. doi: 10.1016/j.ccell.2017.02.004.

14.

PPARδ as a Metabolic Initiator of Mammary Neoplasia and Immune Tolerance.

Glazer RI.

PPAR Res. 2016;2016:3082340. doi: 10.1155/2016/3082340. Epub 2016 Dec 18. Review.

15.
16.

AIB1 Genomic Amplification Predicts Poor Clinical Outcomes in Female Glioma Patients.

Chen L, Wang C, Zhang X, Gao K, Liu R, Shi B, Hou P.

J Cancer. 2016 Oct 22;7(14):2052-2060. eCollection 2016.

17.

Decreased expression of microRNA-17 and microRNA-20b promotes breast cancer resistance to taxol therapy by upregulation of NCOA3.

Ao X, Nie P, Wu B, Xu W, Zhang T, Wang S, Chang H, Zou Z.

Cell Death Dis. 2016 Nov 10;7(11):e2463. doi: 10.1038/cddis.2016.367.

18.

Overexpression of SRC-3 promotes esophageal squamous cell carcinoma aggressiveness by enhancing cell growth and invasiveness.

Xu FP, Liu YH, Luo XL, Zhang F, Zhou HY, Ge Y, Liu C, Chen J, Luo DL, Yan LX, Mei P, Xu J, Zhuang HG.

Cancer Med. 2016 Dec;5(12):3500-3511. doi: 10.1002/cam4.884. Epub 2016 Oct 26.

19.

The Role of Steroid Receptor Coactivators in Hormone Dependent Cancers and Their Potential as Therapeutic Targets.

Wang L, Lonard DM, O'Malley BW.

Horm Cancer. 2016 Aug;7(4):229-35. doi: 10.1007/s12672-016-0261-6. Epub 2016 Apr 28. Review.

20.

NCOA3 coactivator is a transcriptional target of XBP1 and regulates PERK-eIF2α-ATF4 signalling in breast cancer.

Gupta A, Hossain MM, Miller N, Kerin M, Callagy G, Gupta S.

Oncogene. 2016 Nov 10;35(45):5860-5871. doi: 10.1038/onc.2016.121. Epub 2016 Apr 25.

Supplemental Content

Support Center